Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-α

Cytokine and Growth Factor Reviews

Volumn 14, Issue 5, 2003, Pages 447-455

  Ruan, Hong ^a   Lodish, Harvey F ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Adipocyte secreted factors; Adipose tissue; Free fatty acid; Insulin resistance; NF B; Obesity; Tumor necrosis factor

Indexed keywords

ADIPOCYTE COMPLEMENT RELATED PROTEIN OF 30KDA; ADIPOCYTE SECRETED PROTEIN; ADIPONECTIN; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; PROTEIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; AUTOCRINE EFFECT; CELL FUNCTION; ENERGY METABOLISM; GENE EXPRESSION; HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0041374029     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(03)00052-2     Document Type: Review

References (112)

1. Olefsky JM, Ciaraldi TP, Kolterman OG. Mechanisms of insulin resistance in noninsulin-dependent (type II) diabetes. Am J Med 1985;79:12-22.
2. Olefsky JM, Nolan JJ. Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am J Clin Nutr 1995;61:980S-6S.
3. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002;18(Suppl 2):S5-9.
4. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109:S135-48.
5. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
6. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.
7. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
8. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-94.
9. Olefsky JM, Saltiel AR. PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab 2000;11:362-8.
10. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217-24.
11. Stumvoll M, Haring H. Insulin resistance and insulin sensitizers. Horm Res 2001;55(Suppl 2):3-13.
12. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
13. Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. Annu Rev Physiol 2003;65:313-32.
14. Mauvais-Jarvis F, Kulkarni RN, Kahn CR. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clin Endocrinol (Oxf) 2002;57:1-9.
15. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002;3:25-38.
16. Guerra C, Navarro P, Valverde AM, Arribas M, Bruning J, Kozak LP, et al. Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. J Clin Invest 2001;108:1205-13.
17. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000;6:87-97.
18. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissuespecific knockout of the insulin receptor in pancreatic-β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329-39.
19. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-69.
20. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-5.
21. Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol 2000;60:877-83.
22. Jiang G, Zhang BB. Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes. Front Biosci 2002;7:d903-7.
23. Kahn BB. Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 1996;45:1644-54.
24. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002;283:E413-22.
25. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90:3G-10G.
26. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-39.
27. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149-55.
28. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-59.
29. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as 24 precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.
30. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230-6.
31. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 2002;87:226-34.
32. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438-46.
33. Staehr P, Hother-Nielsen O, Landau BR, Chandramouli V, Holst JJ, Beck-Nielsen H. Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes 2003;52:260-7.
34. Laws A. Free fatty acids, insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1996;7:172-7.
35. Saxena U, Witte LD, Goldberg IJ. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. J Biol Chem 1989;264:4349-55.
36. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced-β cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95:2498-502.
37. Ruan H, Miles PDG, Ladd CM, Ross K, Golub TR, Olefsky JM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of TNF-α: implications for insulin resistance. Diabetes 2002;51:3176-88.
38. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxininduced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
39. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4.
40. Kawakami M, Pekala PH, Lane MD, Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 1982;79:912-6.
41. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981;154:631-9.
42. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
43. Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-27.
44. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
45. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, et al. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc Natl Acad Sci USA 1998;95:3408-12.
46. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997;385:729-33.
47. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-67.
48. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
49. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
50. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998;47:1384-91.
51. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-9.
52. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor-α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-8.
53. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
54. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 1994;94:1543-9.
55. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesityinduced insulin resistance in mice lacking TNF-α function. Nature 1997;389:610-4.
56. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-α-mediated insulin resistance in genetic obesity. Endocrinology 1998;139:4832-8.
57. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.
58. Randle P, Garland C, Hales C, Newsholme E. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
59. Randle PJ, Garland PB, Newsholme EA, Hales CN. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 1965;131:324-33.
60. Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X, et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991;88:960-6.
61. Bogardus C, Lillioja S, Stone K, Mott D. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 1984;73:1185-90.
62. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990;322:223-8.
63. Saloranta C, Franssila-Kallunki A, Ekstrand A, Taskinen MR, Groop L. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1991;34:409-15.
64. Ruderman NB, Toews CJ, Shafrir E. Role of free fatty acids in glucose homeostasis. Arch Intern Med 1969;123:299-313.
65. Byrne CD, Brindle NP, Wang TW, Hales CN. Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. Biochem J 1991;280:99-104.
66. Byrne CD, Wang TW, Hales CN. Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. Biochem J 1992;288:101-7.
67. Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein Bcontaining lipoproteins: information obtained from cultured liver cells. J Lipid Res 1993;34:167-79.
68. Boden G. Fatty acids and insulin resistance. Diabetes Care 1996;19:394-5.
69. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65.
70. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47.
71. Reaven GM, Chang H, Ho H, Jeng CY, Hoffman BB. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am J Physiol 1988;254:E23-30.
72. Reaven GM, Chang H, Hoffman BB. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocininduced diabetes. Diabetes 1988;37:28-32.
73. Balasse EO, Neef MA. Influence of nicotinic acid on the rates of turnover and oxidation of plasma glucose in man. Metabolism 1973;22:1193-204.
74. Boden G, Chen X, Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes 1998;47:1609-12.
75. Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA. Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 1990;259:E736-50.
76. Swislocki AL, Chen YD, Golay A, Chang MO, Reaven GM. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (noninsulin-dependent) diabetes. Diabetologia 1987;30:622-6.
77. Skowronski R, Hollenbeck CB, Varasteh BB, Chen YD, Reaven GM. Regulation of non-esterified fatty acid and glycerol concentration by insulin in normal individuals and patients with type 2 diabetes. Diabet Med 1991;8:330-3.
78. Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 1997;17:64-71.
79. Lavoie JM, Bongbele J, Cardin S, Belisle M, Terrettaz J, Van de Werve G. Increased insulin suppression of plasma free fatty acid concentration in exercise-trained rats. J Appl Physiol 1993;74:293-6.
80. Chen YD, Golay A, Swislocki AL, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:17-21.
81. Stralfors P, Bjorgell P, Belfrage P. Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. Proc Natl Acad Sci USA 1984;81:3317-21.
82. Stralfors P, Honnor RC. Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur J Biochem 1989;182:379-85.
83. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 1989;38:1595-601.
84. Campbell PJ, Carlson MG, Hill JO, Nurjhan N. Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification. Am J Physiol 1992;263:E1063-9.
85. Elks ML, Manganiello VC. Antilipolytic action of insulin: role of cAMP phosphodiesterase activation. Endocrinology 1985;116:2119-21.
86. Belfrage P, Fredrikson G, Olsson H, Stralfors P. Molecular mechanisms for hormonal control of adipose tissue lipolysis. Int J Obes 1985;9(Suppl 1):129-35.
87. Belfrage P, Fredrikson G, Nilsson NO, Stralfors P. Regulation of adipose-tissue lipolysis by phosphorylation of hormone-sensitive lipase. Int J Obes 1981;5:635-41.
88. Igal RA, Wang S, Gonzalez-Baro M, Coleman RA. Mitochondrial glycerol phosphate acyltransferase directs the incorporation of exogenous fatty acids into triacylglycerol. J Biol Chem 2001;276:42205-12.
89. Ruan H, Pownall HJ. Overexpression of 1-acyl-glycerol-3-phosphate acyltransferase-α enhances lipid storage in cellular models of adipose tissue and skeletal muscle. Diabetes 2001;50:233-40.
90. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
91. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996;120:803-12.
92. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996;221:286-9.
93. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
94. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9.
95. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 1998;8:335-8.
96. Bogan JS, McKee AE, Lodish HF. Insulin-responsive compartments containing GLUT4 in 3T3-L1 and CHO cells: regulation by amino acid concentrations. Mol Cell Biol 2001;21:4785-806.
97. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes 2002;51:1319-36.
98. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical 33 decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
99. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, et al. Induction of adipocyte complement-related protein of 30 kDa by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
100. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30 kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-10.
101. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
102. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CcC, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-13.
103. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-81.
104. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
105. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-6.
106. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-7.
107. Ma K, Cabrero A, Saha PK, Kojima H, Li L, Chang BH, et al. Increased β-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002;277:34658-61.
108. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-85.
109. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 1996;271:665-8.
110. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001;293:1673-7.
111. Tamori Y, Masugi J, Nishino N, Kasuga M. Role of peroxisome proliferatoractivated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002;51:2045-55.
112. Ruan H, Pownall HJ, Lodish HF. Troglitazone antagonizes TNF-α-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kB. J Biol Chem 2003;278:28181-92.